Title |
Eculizumab in neonatal hemolytic uremic syndrome with homozygous factor H deficiency
|
---|---|
Published in |
Pediatric Nephrology, August 2014
|
DOI | 10.1007/s00467-014-2933-1 |
Pubmed ID | |
Authors |
Katell Michaux, Justine Bacchetta, Etienne Javouhey, Pierre Cochat, Véronique Frémaux-Bacchi, Anne-Laure Sellier-Leclerc |
Abstract |
Neonatal atypical hemolytic uremic syndrome (aHUS) is a rare but severe disease that is mainly due to methylmalonic aciduria or genetic complement abnormalities. Traditional management of aHUS includes plasma infusion/exchange, but in small or unstable infants, plasma exchange can be challenging because of high extracorporeal volume and difficulty to obtain an adequate venous access. The C5 complement blocker eculizumab has become a cornerstone of first-line management of aHUS due to complement deregulation in older patients. However, little data are available on its use in neonatal aHUS. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Members of the public | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Malaysia | 1 | 2% |
Czechia | 1 | 2% |
Unknown | 40 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 8 | 19% |
Other | 7 | 17% |
Researcher | 5 | 12% |
Student > Doctoral Student | 4 | 10% |
Student > Postgraduate | 4 | 10% |
Other | 8 | 19% |
Unknown | 6 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 23 | 55% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 14% |
Nursing and Health Professions | 2 | 5% |
Biochemistry, Genetics and Molecular Biology | 1 | 2% |
Agricultural and Biological Sciences | 1 | 2% |
Other | 4 | 10% |
Unknown | 5 | 12% |